FIELD: chemistry.
SUBSTANCE: invention relates to field of biotechnology, namely to obtaining modified factor FVII, and can be used in medicine. Polypeptide FVII is modified by substitution of amino acid residue, selected from D196L, D196I, D196Y, K197E, K197D, K197L, K197M, K197I, K197V, K197F, K197W, K197Y, K199D and K199E, in amino acid sequence FVII, represented as SEQ ID NO: 3, or in respective residues of its precursor with SEQ ID NO: 1 or SEQ ID NO: 2. Polypeptide can contain additional modifications of amino acids, which improve its functional properties.
EFFECT: invention makes it possible to obtain modified polypeptide FVII, which, when activated, possesses increased coagulant activity and/or increased resistance to inhibitors in comparison with non-modified polypeptide FVII with sequence, given in SEQ ID NO: 3.
48 cl, 7 dwg, 23 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF GLA DOMAIN OF FACTOR VII OR VIIa | 2004 |
|
RU2373282C2 |
| POLYPEPTYDE OF HEMOSTASIS FACTOR VII, PRODUCTION AND APPLICATION | 2001 |
|
RU2326126C2 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
| POLYPEPTIDE OF VII HUMAN COAGULATION FACTOR, PRODUCTION AND APPLICATION | 2002 |
|
RU2325401C2 |
| MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE | 2007 |
|
RU2466141C2 |
| ANTIBODIES AGAINST INHIBITOR OF TISSUE FACTOR METABOLIC PATHWAY | 2009 |
|
RU2562114C2 |
| MODIFIED VITAMIN K DEPENDENT POLYPEPTIDES | 2005 |
|
RU2396347C2 |
| NEW TISSUE FACTOR ANTIBODIES AS ANTICOAGULANTS | 2003 |
|
RU2345789C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING FACTOR VII POLYPEPTIDES AND FACTOR XI POLYPEPTIDES | 2002 |
|
RU2298416C2 |
| MICROVESICLES DERIVED FROM RECOMBINANT YEAST HAVING HAEMOSTATIC ACTIVITIES AND USE THEREOF | 2007 |
|
RU2492184C2 |
